Custom-Made vaccine takes on tough prostate cancer
NCT ID NCT07583160
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a personalized vaccine made from a patient's own immune cells and tumor markers. It aims to help the immune system attack advanced prostate cancer that has stopped responding to standard treatments. About 9 to 18 men will receive four doses over eight weeks to check safety and see if the vaccine can slow the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER (CRPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Changhai Hospital
Shanghai, Shanghai Municipality, 200433, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Old drug, new hope: niclosamide combo targets resistant prostate cancer
- Vaccine-Chemo combo shows promise against spread prostate cancer
- New drug IDE574 enters human trials for Hard-to-Treat cancers
- New pill shows promise against resistant cancers in early trial
- Can a video game teach surgeons to remove prostate cancer?
- Could a few weeks of radiation be enough for recurrent prostate cancer?